Harpoon Therapeutics, Inc. Common Stock
HARP
HARP was delisted on the 8th of March, 2024.
29 hedge funds and large institutions have $128M invested in Harpoon Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
55.55% more ownership
Funds ownership: 0% → 55.55% (+56%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
+$59.5M |
| 2 |
NLVP
New Leaf Venture Partners
New York
|
+$38.4M |
| 3 |
O
OrbiMed
New York
|
+$32.2M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$17.6M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.86M |
Top Sellers
HARP Hedge Fund Activity: Q1 2019 in Review
29 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q1 2019, worth a combined $128M.
Buyers outnumbered sellers: 29 funds opened new HARP positions and 0 closed out — a net gain of 29 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was MPM Asset Management, opening a new position worth an estimated $59.5M.
- 29 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q1 2019, up from 0 in Q4 2018.
- Funds reported $128M of Harpoon Therapeutics, Inc. Common Stock stock for Q1 2019.
- 29 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q1 2019 and 0 closed out, a net change of +29 holders.
- The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q1 2019 was MPM Asset Management, an estimated $59.5M added.
Based on aggregated 13F filings for Q1 2019.